Methotrexate in combination for juvenile rheumatoid arthritis

As with infliximab, standard current practice is therefore to give MTX with etanercept and adalimumab. The same has been shown for adalimumab. Clinical trials in people with early RA have shown that when MTX or etanercept were used as single agents or in combination, those given the combination did much better both in terms of clinical response and x-ray damage than those given either etanercept or MTX alone. The product licence for infliximab states that it should be given in conjunction with methotrexate: this is to reduce the risk of an immune response to one of the components of infliximab which is produced in mice. In many studies in people with an incomplete response to MTX who were given one of these TNF- inhibitors, there was greater improvement in those given the biological agent with the MTX than in those continuing MTX alone. There are currently three agents licensed in the UK for the treatment of RA: infliximab , etanercept and adalimumab. TNF- inhibitors are biological agents which neutralise the effect of TNF-, a pro-inflammatory agent which plays a major role in causing inflammation in RA. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. It has a similar effect to leflunomide, sulphasalazine and cyclosporine, but is less effective than TNF- inhibitors. Several studies have shown that MTX is better at slowing x-ray deterioration than placebo, and also better than azathioprine, penicillamine and auranofin.